NBOMe-escaline, also known as escaline-NBOMe or as N-(2-methoxybenzyl)-4-ethoxy-3,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative psychedelic drug of the phenethylamine, scaline, and N-benzylphenethylamine (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of escaline.
The drug acts as a potent serotonin 5-HT<sub>2A</sub> receptor partial agonist, with an affinity (A<sub>2</sub>) of 0.537nM, an activational potency (K<sub>P</sub>) of 7.08nM, and an intrinsic activity () of 48%. As a serotonin 5-HT<sub>2A</sub> receptor agonist in vitro, it was 7-fold more potent than NBOMe-mescaline, 50-fold more potent than escaline, and 476-fold more potent than mescaline.
NBOMe-escaline was first described in the scientific literature by Heinz Pertz and colleagues by 1999. Along with NBOMe-mescaline, it was one of the first psychedelic N-benzylphenethylamines to be discovered, slightly preceding the publication of 25-NB drugs like 25I-NBOMe by the same group of researchers. NBOMe-escaline is not a controlled substance in Canada as of 2025.